In this comprehensive review, emerging research regarding the role of quiescence in the causation
of acute lymphoblastic leukaemia relapse is explored. This paper by Williams and Gordon
provides a valuable opportunity to gain a deeper understanding of the poor prognosis for those
children who relapse, and allows us to understand the development of potential treatments to
target the complex pathological mechanism of dormancy. Prof Emili Montserrat
Robin Williams,1 *Peter M. Gordon1,2
1. Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, Minnesota, USA
2. University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA
*Correspondence to email@example.com
Disclosure: The authors have declared no conflicts of interest.
Received: 27.03.17 Accepted: 30.05.17
Citation: EMJ Hematol. 2017;5:72-79.
There are ˜3,000 children, as well an additional ˜7,000 adults, diagnosed with acute lymphoblastic leukaemia (ALL) each year in the USA. This makes ALL the most common cancer diagnosed in children. It represents ˜25% of paediatric cancer diagnoses. With current therapy, most patients achieve a complete remission and many are cured. However, the prognosis remains quite poor for the ˜15–20% of children who suffer a relapse of their ALL. Improved outcomes for these relapsed patients will require either more efficacious salvage therapies or improved initial therapy that prevents ALL relapse. Thus, understanding the mechanisms by which a small population of leukaemia cells can escape therapy and contribute to relapse often months or years later is critical for improving ALL outcomes. Herein, we will review emerging clinical and laboratory research that suggest quiescence, or dormancy, is an important cellular mechanism that enhances ALL chemo-resistance and persistence, and ultimately contributes to disease relapse. Furthermore, the mechanisms that regulate this balance between leukaemia quiescence and proliferation are beginning to be elucidated and will provide new knowledge about leukaemia biology. Finally, these observations support the need for and feasibility of therapeutically targeting these quiescent, chemo-resistant ALL cells by either exploiting metabolic or signalling pathway vulnerabilities unique to quiescent cells, or by causing the release of ALL cells from the protective niche(s) that triggers and maintains ALL quiescence.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
The post Editor’s Pick: The Role and Regulation of Quiescence in Acute Lymphoblastic Leukaemia appeared first on European Medical Journal.